RxDoctor Payments Data

Mark Terry, MD

Cornea and External Diseases Specialist · Portland, ORNPI 1760498737

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $81,252 of the $104,124 with a category attached, or 78.0%. 9 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 44.2% of the total.

$104,124in general payments, 2019–2025

Across 43 payments — averaging $2421.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$46K
  • Bausch & Lomb Americas Inc.$45K
  • Moria Inc$10K
  • Eyevance Pharmaceuticals LLC$1K
  • W. L. Gore & Associates, Inc.$1K
  • Alcon$124
  • plus $261 from 3 others

What the payments were for

  • Royalty or licence$81,25278%
  • Consulting fees$2,4502%
  • Speaking & faculty fees$5,0005%
  • Grants$15,00014%
  • Food & beverage$4220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$122,703
Medicare patients
183
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate431$20,140
Fluorometholone181$17,360
Lotemax SmLoteprednol Etabonate13$3,242
Doxycycline Monohydrate33$2,271
Loteprednol Etabonate18$2,208
ValacyclovirValacyclovir Hcl49$1,903
Acyclovir54$1,673
Ofloxacin108$1,243
Doxycycline Hyclate33$698
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$539
Timolol Maleate18$152
ErythromycinErythromycin Base20$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$46,071$5,45031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →